Please check your internet connection and try again.
# Sodium phosphate enema
## Overview
Sodium phosphate enemas are hypertonic saline osmotic laxatives. They act by drawing water into the colonic lumen, inducing distension and stimulating peristalsis. They possess a rapid onset, typically acting within 2–15 minutes.
## Primary Indications
* Relief of occasional constipation.
* Bowel preparation prior to rectal examinations or endoscopic procedures.
## Adult Dosing
* **Standard dose:** One ready-to-use bottle (typically 118 mL volume, containing 19 g monobasic sodium phosphate and 7 g dibasic sodium phosphate).
* **Maximum frequency:** Limited to one dose per 24-hour period.
## Pediatric Dosing
* **Children 2–11 years:** 59 mL (pediatric size enema).
* **Children 12 years and older:** Adult dose (118 mL).
* **Contraindicated:** Do not use in children under 2 years of age due to the risk of severe hyperphosphatemia and electrolyte disturbances.
## Dose Adjustments
* **Renal Impairment:** Use with extreme caution. Contraindicated in patients with renal insufficiency due to the risk of hyperphosphatemia, hypocalcemia, hypernatremia, and acidosis.
* **Elderly:** Use caution; age-related decrease in renal function increases the risk of systemic absorption and electrolyte toxicity.
## Contraindications
* Known hypersensitivity to sodium phosphates.
* Renal failure or significant impairment.
* Congestive heart failure (due to sodium load).
* Megacolon, bowel obstruction, or perforation.
* Appendicitis, acute surgical abdomen, or inflammatory bowel disease (active).
* Fecal impaction.
## Adverse Effects
* **Electrolyte disturbances:** Hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia.
* **Local:** Rectal irritation, burning, or bleeding (if administered forcefully).
* **Systemic:** Dehydration, metabolic acidosis, and rarely, seizures (secondary to severe electrolyte imbalance).
## Key Drug Interactions
* **Diuretics:** Increased risk of dehydration and electrolyte imbalances.
* **Antihypertensives/ACE inhibitors/ARBs:** Increased risk of renal damage or electrolyte shifts.
* **Calcium channel blockers/Bisphosphonates:** Risk of additive effect on hypocalcemia.
* **Medications containing phosphates:** Avoid concurrent use to prevent phosphate toxicity.
## Monitoring
* Monitor for signs of electrolyte toxicity: lethargy, confusion, muscle twitching, or seizures.
* Monitor hydration status.
* In repeat-use scenarios (non-standard), monitor serum electrolytes (calcium, phosphorus, sodium, potassium) and creatinine.
## Clinical Pearls
* **Administration:** Instruct patient to lie on the left side with knees bent (Sims' position) to facilitate anatomical flow. Do not force the tip into the rectum to avoid perforation.
* **Safety Warning:** Ensure the patient is adequately hydrated before administration to mitigate the risk of severe dehydration.
* **Refractory symptoms:** If bowel movement does not occur after administration, the patient must be instructed to discontinue use and consult a physician to rule out obstruction.
* **Local Protocols:** Institutional protocols for procedural bowel preparation may differ from OTC labeling; always verify specific facility-based guidelines.
***
**Disclaimer:** This information is for educational purposes and does not supersede local clinical guidelines. Always consult the latest institutional policies, physician desk references, or current electronic health record formulary databases before prescribing or administering medication.
